- 442. Scottish Intercollegiate Guidelines Network (SIGN). Pharmacological management of asthma. Evidence table 4.15: mometasone furoate dry powder inhalation. 2002. Available from http://www.sign.ac.uk/guidelines/published/support/guideline63/table4.15.html: [Accessed. 10 July 2014].
- 443. Woodcock A, Bateman ED, Busse WW, Lotvall J, Snowise NG, Forth R, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respiratory Research 2011;12:132.
- 444. Woodcock A, Bleecker ER, Busse WW, Lotvall J, Snowise NG, Frith L, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respiratory Research 2011;12:160.
Environmental impact of inhaler devices
This content is from the BTS/SIGN British guideline on the management of asthma (SIGN 158), 2019.
Metered dose inhalers contain propellants which are liquefied, compressed gases used as a driving force and an energy source for atomisation of the drug. Chlorofluorocarbons (CFCs), which were used originally, are potent greenhouse gases and ozone-depleting substances, and were phased out under the Montreal Protocol. They have been replaced by two hydrofluoroalkane (HFA) propellants: 1,1,1,2-tetrafluoroethane (HFA134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA227ea), identified as having a high global-warming potential.542 As a result of this change, MDIs currently contribute an estimated 3.5% of the carbon footprint of the NHS in the UK.543 The UK has a high proportion of MDI use (70%) compared with the rest of Europe (< 50%) and Scandinavia (10–30%).544
[BTS/SIGN 2019]
[BTS/SIGN 2019]